Fasitibant

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

353 Data

Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Fasitibant.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Fasitibant.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fasitibant.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fasitibant.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fasitibant.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fasitibant.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Fasitibant.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fasitibant.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fasitibant.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fasitibant.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Fasitibant.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fasitibant.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fasitibant.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Fasitibant.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fasitibant.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fasitibant.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Fasitibant.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Fasitibant.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Fasitibant.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fasitibant.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Fasitibant.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fasitibant.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Fasitibant.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Fasitibant.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fasitibant.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fasitibant.
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Fasitibant.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fasitibant.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Fasitibant.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Fasitibant.
Cladribine	Fasitibant may increase the immunosuppressive activities of Cladribine.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Fasitibant.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Fasitibant.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fasitibant.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fasitibant.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fasitibant.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Fasitibant.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Fasitibant.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Fasitibant.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Fasitibant.
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Fasitibant.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Fasitibant.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Fasitibant.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Fasitibant.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fasitibant.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fasitibant.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Fasitibant.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Fasitibant.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Fasitibant.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Fasitibant.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Fasitibant.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Fasitibant.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Fasitibant.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fasitibant.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fasitibant.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Fasitibant.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Fasitibant.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Fasitibant.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fasitibant.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Fasitibant.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Fasitibant.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fasitibant.
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Fasitibant.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fasitibant.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Fasitibant.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Fasitibant.
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Fasitibant.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Fasitibant.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fasitibant.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Fasitibant.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Fasitibant.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Fasitibant.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Fasitibant.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Fasitibant.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Fasitibant.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Fasitibant.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fasitibant.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fasitibant.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fasitibant.
Irinotecan	The risk or severity of adverse effects can be increased when Irinotecan is combined with Fasitibant.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Fasitibant.
Mometasone	The risk or severity of adverse effects can be increased when Mometasone is combined with Fasitibant.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Fasitibant.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fasitibant.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fasitibant.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Fasitibant.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Fasitibant.
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Fasitibant.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Fasitibant.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Fasitibant.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Fasitibant.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Fasitibant.
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fasitibant.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fasitibant.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Fasitibant.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Fasitibant.
Doxorubicin	The risk or severity of adverse effects can be increased when Doxorubicin is combined with Fasitibant.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Fasitibant.
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Fasitibant.
Clobetasol propionate	The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fasitibant.

Target Protein

B2 bradykinin receptor BDKRB2

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual